Investors Overview
Overview
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
Minimum 15 minutes delayed. Source: LSEG
News Releases
23
Dec '24
19
Dec '24
13
Nov '24
07
Nov '24
Recent Events
November 13, 2025 at 8:00 AM EST
August 14, 2025 at 8:00 AM EDT
May 28, 2025 at 9:00 AM CEST
Latest Financials
Press Release Q3 2024 398.3 KB
Presentation Q3 2024 1.8 MB
Fréttatilkynning Q3 2024 445.9 KB
Presentation Q2 2024 2.2 MB